Immuron LtdIMRN
Price (close)
$1.19
Market cap
$9.6M
P/E
—
Revenue (FY)
$7.3M
Net income
-$5.2M
Dividend yield
—
1-year total return
-38.3%
Net margin
-71.6%
Revenue growth
48.6%
Debt / equity
—
What Immuron Ltd does.
biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of
specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs. Our oral polyclonal antibodies
offer delivery within the gastrointestinal (“GI”) tract and our technology platform can be used to target viruses or bacteria
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $2.5M | $145,776 | $765,193 | $1.8M | $4.9M | $7.3M |
| Net income | -$2.9M | -$8.4M | -$2.9M | -$3.8M | -$6.9M | -$5.2M |
| Free cash flow | -$3.1M | -$4.1M | -$3.2M | -$2.6M | -$5.9M | — |
More on IMRN.
- Immuron Ltd summary
- Immuron Ltd financial statements
- Immuron Ltd key metrics
- Immuron Ltd health scores and style box
- Immuron Ltd earnings
- Immuron Ltd dividends
- Immuron Ltd valuation
- Immuron Ltd ownership and insiders
- Immuron Ltd peers
Figures from Immuron Ltd's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.